Venus Medtech, a Chinese company that produces heart valve replacement devices, plans to raise up to $381 million in an initial public offering (IPO) in Hong Kong next month against headwinds including civil unrest in the Asian financial hub for nearly six months.
The Chinese developer of cardiovascular devices filed paperwork with the Hong Kong stock exchange late Monday to proceed with its offering and began taking orders on Tuesday.
The company plans to offer 78.5 million shares at a price range between HK$29 and HK$33 apiece, with an expected listing on December 10. It would raise as much as $381 million if an over-allotment of shares is fully exercised.
The IPO of Venus Medtech comes as Hong Kong has suffered from almost six months of anti-government protests this year, at times forcing schools, transportation, businesses, and government to close.
The situation was further escalated after U.S. President Donald Trump on Wednesday signed into law congressional legislation supporting protesters in Hong Kong despite objections from the central government in China.
Against headwinds of the civil unrest in Hong Kong and China’s gloomy economic condition, Venus Medtech is joining a cluster of biotech companies to restore investors’ confidence in the financial market in Hong Kong.
Since the city bourse introduced new rules to allow listings of pre-profit biotech firms, 15 biotech companies have gathered a total of HK$48.6 billion ($6.21 billion) through IPOs in Hong Kong by August 2019, turning the city into the second-largest fundraising centre for biotech companies globally, according to official statistics.
Amongst these companies, eight pre-revenue biotech firms have raised HK$23.5 billion, and several IPOs have completed within the contract research organization (CRO) and medical services space.
Venus Medtech, founded in 2009, develops trans-catheter heart valve medical devices for the treatment of structural heart diseases in China. The company had a 79.3 per cent market share in the country in terms of device implants in 2018, according to Frost & Sullivan, cited in its prospectus. It counts Asia-focused private equity firm Hillhouse Capital and Singaporean sovereign wealth fund GIC among cornerstone investors.
The company, which first filed in early August, reported a loss of 138.2 million yuan ($19.7 million) in the first five months of 2019, compared with a loss of 50.2 million yuan in the same period last year.
Proceeds from the IPO will be used to commercialise its VenusA-Valve product, as well as for research and development and general corporate purposes. VenusA-Value, a self-developed product of Venus Medtech, is the first transcatheter aortic valve replacement (TAVR) device approved by China’s National Medical Products Administration and commercialised in the mainland, shows the prospectus.
Goldman Sachs, CICC, Credit Suisse and CMS are acting as joint sponsors on the deal.